234 related articles for article (PubMed ID: 38202077)
21. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
23. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
Ghione P; Salles G
Haematologica; 2024 May; ():. PubMed ID: 38813707
[TBL] [Abstract][Full Text] [Related]
28. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Harris LJ; Patel K; Martin M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
30. Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Gonzalez Barca E
J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068428
[TBL] [Abstract][Full Text] [Related]
31. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W
Expert Opin Biol Ther; 2021 Apr; 21(4):455-463. PubMed ID: 33554668
[TBL] [Abstract][Full Text] [Related]
32. The use of tafasitamab in diffuse large B-cell lymphoma.
Düll J; Topp M; Salles G
Ther Adv Hematol; 2021; 12():20406207211027458. PubMed ID: 34285786
[TBL] [Abstract][Full Text] [Related]
33. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
34. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
35. Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients.
Douglas M
J Adv Pract Oncol; 2020 Jul; 11(5):521-528. PubMed ID: 32974076
[TBL] [Abstract][Full Text] [Related]
36. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
37. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
38. Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma.
Assi R; Masri N; Dalle IA; El-Cheikh J; Ghanem H; Bazarbachi A
Clin Hematol Int; 2021 Mar; 3(1):21-26. PubMed ID: 34595463
[TBL] [Abstract][Full Text] [Related]
39. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
[TBL] [Abstract][Full Text] [Related]
40. Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.
Papageorgiou SG; Thomopoulos TP; Liaskas A; Vassilakopoulos TP
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]